Open Access

Correction to: Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study

  • Sandra Wagner1, 2,
  • Marie Metzger1,
  • Martin Flamant3,
  • Pascal Houillier4, 5,
  • Jean-Philippe Haymann6,
  • François Vrtovsnik3,
  • Eric Thervet5, 7,
  • Jean-Jacques Boffa6,
  • Ziad A. Massy1, 2, 8,
  • Bénédicte Stengel1, 2Email author,
  • Patrick Rossignol2, 9 and
  • for the NephroTest Study group
BMC NephrologyBMC series – open, inclusive and trusted201718:308

https://doi.org/10.1186/s12882-017-0723-2

Received: 22 September 2017

Accepted: 22 September 2017

Published: 6 October 2017

The original article was published in BMC Nephrology 2017 18:295

In the original version of this article [1], published on 12 September 2017, the explanation of a and b in the footnote of Table 2 were switched during typesetting. In this Correction Table 2, the incorrect and correct version of its footnote are shown. The affected part of the footnote is marked in italics. The original publication of this article has been corrected.
Table 2

Odds ratios of low or high plasma potassium associated with baseline patient characteristics – Multinomial logistic regression using patients with plasma potassium of 4–5 mmol/L as the reference group

  

Plasma potassium (mmol/L)

<4

>5

Age (per year)

 

0.99 (0.98–1.00)

0.98 (0.96–0.99)

Women vs men

 

1.49 (1.16–1.90)

0.47 (0.30–0.72)

Sub-Saharan vs other ethnicity

1.35 (0.99–1.83)

1.15 (0.66–1.99)

mGFR (ml/min/1.73m2)

 

<15

0.11 (0.05–0.23)

29.65 (10.87–80.88)

 

15–30

0.26 (0.18–0.38)

13.58 (5.71–32.3)

 

30–45

0.47 (0.34–0.63)

5.70 (2.42–13.45)

 

45–60

0.67 (0.49–0.90)

2.70 (1.07–6.85)

 

>60

1

1

BMI

 

<19

1.46 (0.83–2.59)

1.49 (0.65–3.43)

 

19–25

1

1

 

25–30

0.85 (0.66–1.10)

0.78 (0.51–1.20)

 

>30

0.78 (0.57–1.07)

1.05 (0.65–1.73)

Smoking status

 

Never smoked

1

1

 

Former smoker

0.85 (0.66–1.11)

1.02 (0.67–1.54)

 

Active smoker

0.76 (0.54–1.06)

1.66 (1.03–2.67)

Mean blood pressure (per mmHg)

1.01 (1.00–1.02)

1.01 (0.99–1.02)

Cardio-vascular history

0.63 (0.46–0.88)

0.81 (0.51–1.28)

ACR (mg/mmol)

 

<3

1

1

 

3–30

1.07 (0.82–1.40)

1.25 (0.76–2.08)

 

>30

0.80 (0.59–1.10)

1.13 (0.67–1.90)

Diabetes

 

0.86 (0.66–1.13)

1.56 (1.04–2.34)

Urine potassium

0.99 (0.99–1.00)

1.01 (1.00–1.01)

Serum albumin

 

≥35

1

1

 

<35

1.23 (0.87–1.74)

1.23 (0.76–1.98)

Serum potassium increasing drugsa

 

0.58 (0.44–0.78)

2.50 (1.17–5.35)

Serum potassium-lowering drugsb

1.70 (1.33–2.17)

1.01 (0.69–1.49)

a loop or thiazide diuretic, kayexalate or bicarbonates b ACEi or ARBs or potassium-sparing diuretics

BMI body mass index, CVD cardiovascular disease, mGFR measured GFR, ACR, ratio of urinary albumin to creatinine

The analyses was adjusted for center

Table 2

Odds ratios of low or high plasma potassium associated with baseline patient characteristics – Multinomial logistic regression using patients with plasma potassium of 4–5 mmol/L as the reference group

  

Plasma potassium (mmol/L)

<4

>5

Age (per year)

 

0.99 (0.98–1.00)

0.98 (0.96–0.99)

Women vs men

 

1.49 (1.16–1.90)

0.47 (0.30–0.72)

Sub-Saharan vs other ethnicity

1.35 (0.99–1.83)

1.15 (0.66–1.99)

mGFR (ml/min/1.73m2)

 

<15

0.11 (0.05–0.23)

29.65 (10.87–80.88)

 

15–30

0.26 (0.18–0.38)

13.58 (5.71–32.3)

 

30–45

0.47 (0.34–0.63)

5.70 (2.42–13.45)

 

45–60

0.67 (0.49–0.90)

2.70 (1.07–6.85)

 

>60

1

1

BMI

 

<19

1.46 (0.83–2.59)

1.49 (0.65–3.43)

 

19–25

1

1

 

25–30

0.85 (0.66–1.10)

0.78 (0.51–1.20)

 

>30

0.78 (0.57–1.07)

1.05 (0.65–1.73)

Smoking status

 

Never smoked

1

1

 

Former smoker

0.85 (0.66–1.11)

1.02 (0.67–1.54)

 

Active smoker

0.76 (0.54–1.06)

1.66 (1.03–2.67)

Mean blood pressure (per mmHg)

1.01 (1.00–1.02)

1.01 (0.99–1.02)

Cardio-vascular history

0.63 (0.46–0.88)

0.81 (0.51–1.28)

ACR (mg/mmol)

 

<3

1

1

 

3–30

1.07 (0.82–1.40)

1.25 (0.76–2.08)

 

>30

0.80 (0.59–1.10)

1.13 (0.67–1.90)

Diabetes

 

0.86 (0.66–1.13)

1.56 (1.04–2.34)

Urine potassium

0.99 (0.99–1.00)

1.01 (1.00–1.01)

Serum albumin

 

≥35

1

1

 

<35

1.23 (0.87–1.74)

1.23 (0.76–1.98)

Serum potassium increasing drugsa

 

0.58 (0.44–0.78)

2.50 (1.17–5.35)

Serum potassium-lowering drugsb

1.70 (1.33–2.17)

1.01 (0.69–1.49)

a ACEi or ARBs or potassium-sparing diuretics b loop or thiazide diuretic, kayexalate or bicarbonates

BMI, body mass index, CVD, cardiovascular disease, mGFR, measured GFR, ACR, ratio of urinary albumin to creatinine

The analyses was adjusted for center

Originally Table 2 and its footnote were published as followed:

The analyses was adjusted for center

The correct version of Table 2 and its footnote is:

The analyses was adjusted for center

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
CESP, Inserm U1018, Univ Paris-Saclay, Univ Paris-Sud, UVSQ
(2)
FCRIN INI-CRCT
(3)
Bichat Hospital
(4)
INSERM U1138
(5)
HEGP
(6)
Tenon Hospital
(7)
INSERM, UMRS970
(8)
Ambroise Paré Hospital
(9)
INSERM CIC 1433, Nancy CHRU and University of Lorraine

Reference

  1. Wagner et al. Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study (2017) 18:295 DOI 10.1186/s12882-017-0710-7Google Scholar

Copyright

© The Author(s). 2017

Advertisement